T1	Participants 74 118	autosomal dominant polycystic kidney disease
T2	Participants 213 254	end-stage kidney failure in most patients
T3	Participants 575 594	patients with ADPKD
T4	Participants 596 713	Sixty patients were initially recruited but 49 of these received either pravastatin 20 mg or no treatment for 2 years
